Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda launches phase III trial of new Hib vaccine

Takeda launches phase III trial of new Hib vaccine

15th June 2011

Takeda has announced the commencement of a new phase III clinical trial of a developmental Haemophilus Influenzae type b (Hib) vaccine.

Taking place in Japan, the study will aim to evaluate the efficacy of TAK-816 in preventing infections caused by the disease, which is a well-known cause of bacterial meningitis.

A licensing deal for the liquid form vaccine treatment was agreed with Novartis in 2009, with the agent offering improved immunogenicity through its combination of polyribosylribitol phosphate with a non-toxic mutation of diphtheria toxin.

Masato Iwasaki, corporate officer and senior vice-president for the strategic product planning department of Takeda, said the company is also planning to test combination treatments that utilise the compound in future.

"We will promote the development of TAK-816 and provide the product for patients as soon as possible to fulfil our social responsibilities as a pharmaceutical company," he added.

Last month, Takeda announced that it will be expanding its European presence via the acquisition of fellow drug manufacturer Nycomed.ADNFCR-8000103-ID-800579328-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.